Macquarie Initiates Buy Target on Divi's Laboratories Ltd with 27% Upside Potential

The shares of a Large-cap company specializing in the manufacturing of Generic Active Pharmaceutical Ingredients (APIs), custom synthesis of APIs and intermediates for global pharmaceutical companies, and nutraceutical ingredients are in the spotlight as Macquarie has initiated a buy target with an upside of 27 percent. With a market capitalization of Rs. 2,20,449.09 crores in the day’s trade, the shares of rose upto 4.5 percent, reaching a high of Rs. 8,417.25 per share compared to its previous closing price of Rs. 8,056.65 per share. Divis Laboratories Ltd engaged in the manufacturing of Generic Active Pharmaceutical Ingredients (APIs), custom synthesis of APIs and intermediates are in focus as the global brokerage report, Macquarie, maintains an “Outperform” rating and has increased its target price to Rs. 10,200, indicating an upside potential of 27% from the previous closing price of Rs. 8,056.65. Divi’s Laboratories is strategically placed to capitalize on the booming peptide CDMO segment, with increasing demand for peptide drug products, particularly in diabetes and obesity drugs. Revenue growth is forecast over the long term through this segment of the business. An integrated manufacturing system is beneficial for managing cost, quality, and production efficiency. This gives Divi’s Laboratories an edge over other competitors vying for CDMO clients among the global pharmaceutical players. There is an upswing in outsourcing of complex molecule manufacture from pharma companies. Divi’s capabilities, compliance, and strong record of execution make it well suited to benefit from the increasing global CDMO market opportunity. The Outperform rating on Divi remains intact while the target price is raised to Rs. 10,200 due to optimism about its future growth potential. Growth in peptide manufacturing, good customer relations, and enhanced profitability make it merit a premium valuation. Divi’s focus on high-complexity products and advanced manufacturing capabilities provides a sustainable growth advantage. Its ability to develop and scale specialized pharmaceutical ingredients supports long-term profitability and strengthens its position in global markets. Revenue from Operations increased by 27.8 percent YoY, from Rs. 2,410 crore in Q1 FY26 to Rs. 3,080 crore in Q1 FY27. It also increased by 8.8 percent QoQ, from Rs. 2,831 crore in Q4 FY26 to Rs. 3,080 crore in Q1 FY27. Net profit increased by 65.5 percent YoY, from Rs. 545 crore in Q1 FY26 to Rs. 902 crore in Q1 FY27. It also increased by 20.1 percent QoQ, from Rs. 751 crore in Q4 FY26 to Rs. 902 crore in Q1 FY27. The company demonstrates strong operational efficiency with a ROCE of 22.0% and a ROE of 16.5%, indicating effective utilization of capital and shareholders’ funds. Its debt-to-equity ratio of 0.00 reflects a debt-free balance sheet and a financially stable position. The company maintains a healthy 39.0% dividend payout ratio, reflecting its consistent shareholder returns while balancing earnings retention for sustainable growth and future expansion opportunities. Divi’s Laboratories Limited is a pharmaceutical firm based in India that specializes in producing APIs, intermediates, and nutraceutical ingredients. The company was founded in 1990. In addition to manufacturing and exporting various APIs, intermediates, and nutraceutical ingredients, Divi’s Laboratories Limited offers contract manufacturing services to international pharmaceutical firms. It is known for its strong presence in the global API market, supplying products to many countries, including regulated markets such as the US and Europe. The company focuses on high-quality manufacturing, research, innovation, and sustainable pharmaceutical solutions. Sridhar is a NISM-certified Research Analyst with an MBA in Finance and with over 3+ years of experience as a Financial Analyst, possessing strong expertise in both fundamental and technical analysis. Specialises in equity research, company and sector evaluation, IPO analysis, and tracking market trends to produce clear, investor-friendly insights.